IL248704A0 - טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2 - Google Patents
טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2Info
- Publication number
- IL248704A0 IL248704A0 IL248704A IL24870416A IL248704A0 IL 248704 A0 IL248704 A0 IL 248704A0 IL 248704 A IL248704 A IL 248704A IL 24870416 A IL24870416 A IL 24870416A IL 248704 A0 IL248704 A0 IL 248704A0
- Authority
- IL
- Israel
- Prior art keywords
- radiotherapy
- treatment
- positive cancers
- immuno therapy
- combination
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000011220 combination immunotherapy Methods 0.000 title 1
- 238000011258 immunoradiotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US201462076411P | 2014-11-06 | 2014-11-06 | |
PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
US14/669,629 US10016617B2 (en) | 2009-11-11 | 2015-03-26 | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
PCT/US2015/024048 WO2015167748A1 (en) | 2014-05-02 | 2015-04-02 | Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
IL248704A0 true IL248704A0 (he) | 2017-01-31 |
Family
ID=54359144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL248704A IL248704A0 (he) | 2014-05-02 | 2016-11-02 | טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3137107A4 (he) |
JP (1) | JP2017514904A (he) |
KR (1) | KR20170002552A (he) |
CN (1) | CN106794234A (he) |
AU (1) | AU2015253737A1 (he) |
CA (1) | CA2947677A1 (he) |
IL (1) | IL248704A0 (he) |
MA (1) | MA39942A (he) |
MX (1) | MX2016014367A (he) |
SG (1) | SG11201609135VA (he) |
WO (1) | WO2015167748A1 (he) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | ADJUVANZIA ON LISTERIA BASE |
SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
SG11201606677XA (en) | 2014-02-18 | 2016-09-29 | Advaxis Inc | Biomarker directed multi-target immunotherapy |
SG11201608820WA (en) | 2014-04-24 | 2016-11-29 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
US20190134174A1 (en) * | 2016-06-03 | 2019-05-09 | Etubics Corporation | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu |
JP7197481B2 (ja) | 2016-11-30 | 2022-12-27 | アドバクシス, インコーポレイテッド | 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法 |
WO2019060115A1 (en) | 2017-09-19 | 2019-03-28 | Advaxis, Inc. | COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
AU2004281834A1 (en) * | 2003-10-15 | 2005-04-28 | Cerus Corporation | Listeria-based EphA2 vaccines |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
EP2498808A4 (en) * | 2009-11-11 | 2014-01-08 | Advaxis | COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION |
US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
CN102947452A (zh) * | 2010-05-23 | 2013-02-27 | 艾杜罗生物科技公司 | 使用用于癌症的辅佐治疗的李斯特菌属的方法和组合物 |
-
2015
- 2015-04-02 CN CN201580036168.0A patent/CN106794234A/zh active Pending
- 2015-04-02 CA CA2947677A patent/CA2947677A1/en not_active Abandoned
- 2015-04-02 WO PCT/US2015/024048 patent/WO2015167748A1/en active Application Filing
- 2015-04-02 MA MA039942A patent/MA39942A/fr unknown
- 2015-04-02 JP JP2017509588A patent/JP2017514904A/ja not_active Ceased
- 2015-04-02 MX MX2016014367A patent/MX2016014367A/es unknown
- 2015-04-02 AU AU2015253737A patent/AU2015253737A1/en not_active Abandoned
- 2015-04-02 SG SG11201609135VA patent/SG11201609135VA/en unknown
- 2015-04-02 KR KR1020167033949A patent/KR20170002552A/ko unknown
- 2015-04-02 EP EP15786740.9A patent/EP3137107A4/en not_active Withdrawn
-
2016
- 2016-11-02 IL IL248704A patent/IL248704A0/he unknown
Also Published As
Publication number | Publication date |
---|---|
CA2947677A1 (en) | 2015-11-05 |
KR20170002552A (ko) | 2017-01-06 |
CN106794234A (zh) | 2017-05-31 |
JP2017514904A (ja) | 2017-06-08 |
MA39942A (fr) | 2017-03-08 |
EP3137107A4 (en) | 2018-01-17 |
MX2016014367A (es) | 2017-06-30 |
AU2015253737A1 (en) | 2016-12-22 |
WO2015167748A1 (en) | 2015-11-05 |
SG11201609135VA (en) | 2016-11-29 |
EP3137107A1 (en) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL297418B1 (he) | טיפול חיסוני משולב וטיפול בקרת ציטוקין לטיפול בסרטן | |
IL291844B1 (he) | טיפול משולב smc לטיפול בסרטן | |
IL290149A (he) | טיפול משולב לטיפול בסרטן | |
IL261008A (he) | טיפול חיסוני משולב וטיפול בקרת ציטוקין לטיפול בסרטן | |
IL272740A (he) | טיפול חיסוני משולב וטיפול בקרת ציטוקין לטיפול בסרטן | |
GB201719076D0 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
HK1247129A1 (zh) | 治療癌症的聯合療法 | |
IL267795A (he) | טיפול משולב לטיפול בסרטן | |
HK1251475A1 (zh) | 用於癌症治療的聯合療法 | |
SG11201700079VA (en) | Combination therapy compositions and methods for treating cancers | |
IL248704A0 (he) | טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2 | |
IL274837B1 (he) | טיפול משולב לטיפול בסרטן | |
LT3622953T (lt) | Kombinuotas vėžio gydymas | |
IL266993A (he) | תרפיה משולבת לטיפול בסרטן | |
IL275517A (he) | שיטות וטיפול מצרפי בסרטן | |
IL264589A (he) | טיפול משולב לטיפול בסרטן הלבלב | |
IL258494A (he) | טיפול משולב רציונלי לטיפול בסרטן | |
IL253642A0 (he) | טיפול משולב לטיפול בסרטן | |
GB201704474D0 (en) | Combination therapy for treatment of cancer | |
GB201717004D0 (en) | Methods of cancer therapy | |
GB201711769D0 (en) | Methods of cancer therapy | |
GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer |